Natural Capsules Limited Releases Q2FY26 Investor Presentation, Reports Profitability Decline Amidst Challenges
Natural Capsules Limited reported Q2FY26 results with revenue growth but significant declines in profitability due to US tariffs on HPMC capsules and API scale-up delays. A new production line is expected by Q3FY26.
The sharp decline in profitability metrics like EBITDA and PAT, coupled with the impact of US tariffs on the core capsules business and persistent technical difficulties in the API segment, indicates a high negative impact on the company's financial health and near-term growth trajectory.
The company reported significant declines in EBITDA, PAT, and EPS for Q2FY26. Profitability was negatively impacted by US tariffs on HPMC capsules and technical challenges in scaling up API production, leading to a tough year and delayed growth.
* Natural Capsules Limited (NCL) has released an investor presentation for its unaudited Standalone & Consolidated Financial Results for the quarter and half year ended September 30, 2025. * For Q2FY26 (Consolidated), the company reported: * Revenue from Operations: ₹45.80 crore, a 1.33% increase quarter-on-quarter (Q-o-Q) and 11.11% year-on-year (Y-o-Y). * EBITDA: ₹(0.88) crore, a significant decline of 377.07% Q-o-Q and 119.63% Y-o-Y. * EBITDA Margins: (1.93%), down 264 basis points (bps) Q-o-Q and 1286 bps Y-o-Y. * Profit After Tax (PAT): ₹(6.99) crore, a decrease of 25.24% Q-o-Q and 1041.62% Y-o-Y. * EPS: ₹(6.76), down 25.19% Q-o-Q and 1026.67% Y-o-Y. * Management Commentary (Sunil Mundra, Managing Director): * Q2FY26 was stable for the capsules business, with steady demand and performance in line with guidance. * Growth from HPMC capacity expansion was impacted by US tariffs on Indian exports, affecting demand in the US market. * The company remains on track with its capital expenditure plan and expects to commission a new production line by the end of Q3FY26 (December 2025). * Growth in the capsules segment is anticipated to pick up once there is clarity on tariffs. * The API segment continues to face challenges, with technical difficulties in scaling up fermentation batches delaying commercial production ramp-up, which was initially aimed for Q3FY26. * FY26 has been tough due to US tariffs and delays/technical issues in API plant scale-up. A notable development was the US imposing an 88% duty on Chinese HPMC capsules compared to 14% on Indian HPMC capsules. * Under the Production Linked Incentive (PLI) scheme, NCL expects to receive incentives amounting to approximately ₹67 crore over six years, which is expected to de-risk the company’s investments significantly.
What to do with a filing like this
Natural Capsules Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natural Capsules Limited. Read the original for the full detail.